Glen Goss

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)

Yvon Cormier, E. Eisenhauer, A. Muldal et al. · Annals of Oncology · 1994 · 146 citations

Medicine, Pharmacology, Active New Agent +5

A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.

Glen Goss, Ian Lorimer, Ming‐Sound Tsao et al. · Journal of Clinical Oncology · 2010 · 76 citations

Surgical Oncology, Early Stage Nsclc, Cancer Management +17

Oral Etoposide and Carboplatin

William K. Evans, Amer Radwi, Eva Tomiak et al. · American Journal of Clinical Oncology · 1995 · 68 citations

Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort

Niloofar Taghizadeh, Alain Tremblay, Sonya Cressman et al. · BMJ Open · 2019 · 55 citations · Full text

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

Martin Gore, R Powles, A. Lakhani et al. · Cancer Chemotherapy and Pharmacology · 1989 · 34 citations

Hematological Malignancy, Refractory Acute Leukaemia, Medicine +11